Acadian Asset Management LLC increased its stake in Aclaris Therapeutics, Inc. (NASDAQ:ACRS) by 25.9% in the first quarter, owning 2,195,191 shares. Aclaris recently announced success in a Phase 2a trial of ATI-2138 for atopic dermatitis, to be presented at the 2025 EADV Congress. ATI-2138 is a selective oral covalent inhibitor of ITK and JAK3, showing promise in treating the condition. Aclaris is a Pennsylvania-based biopharmaceutical company focused on immune-inflammatory diseases. While ACRS is a potential investment, consider other AI stocks for greater upside potential and less risk.

Read more at Yahoo Finance: Acadian Increases Stake in Aclaris Therapeutics, Inc. (ACRS) as Phase 2a Data Gains Spotlight